Skip to Content

Reckitt Benckiser Group PLC ADR RBGLY

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Reckitt Misses on First-Half Margins but Has the Pricing Power to Rebuild Margins For Next Year

Analyst Note

| Philip Gorham, CFA, FRM |

Reckitt missed our forecasts at the gross margin in the first half of 2021 due to rising commodity costs. Given the continuing spikes in raw materials in recent months, it is unlikely to be the last company to do so this reporting season. With inflationary pressures currently greater than Reckitt’s ability to raise prices, we expect the gross margin to continue to be weak in the short term, with further margin degredation in the second half of the year. However, the market sell-off of the stock is an overreaction, in our view, and we do not believe this report wipes 8% off the intrinsic value of the stock. In fact, we believe Reckitt is better positioned than most to pass through the cost inflation to consumers, with parts of the consumer health and formula businesses holding fairly strong pricing power. Nevertheless, we are lowering our gross margin estimates for this year and next, and we are cutting our fair value estimate to GBX 6,500 per share from GBX 6,800 to reflect the short-term margin squeeze. We think the sell-off has created a somewhat attractive entry point.

Read Full Analysis

Company Profile

Business Description

European firms Reckitt & Coleman and Benckiser combined in 1999 to form Reckitt Benckiser, which recently rebranded to the corporate name Reckitt. The firm's products include a variety of household and personal-care brands, such as Calgon, Lysol, Finish, and Mucinex, many of which have the number-one or -two position in their categories. More recently, Reckitt has repositioned its portfolio, and has entered infant formula through the acquisition of Mead Johnson, expanded its consumer health presence by acquiring SSL International, Schiff Nutrition, and K-Y, and has exited the food industry. The firm operates in 60 countries and sells products in more than 200, generating around 40% of sales from emerging markets.

Contact
103-105 Bath Road
Slough, Berkshire, SL1 3UH, United Kingdom
T +44 1753217800
Sector Consumer Defensive
Industry Household & Personal Products
Most Recent Earnings Dec 31, 2011
Fiscal Year End Dec 31, 2021
Stock Type
Employees 38,945

Related

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.